Antibody Persistence and Risk of COVID-19 Infection: Insights from Modeling
Risk of infection decreased with increasing nAb titers for all vaccines. Statistical models predicted significantly better antibody persistence for the B.1.351 booster formulation compared to the other evaluated vaccines.
Authors
- Laurent Coudeville (ORCID: https://orcid.org/0000-0003-3651-2959)
- Eleine Konaté
- Scott D. Patterson (ORCID: https://orcid.org/0000-0002-9840-4964)
- Clotilde El Guerche‐Séblain (ORCID: https://orcid.org/0000-0003-0196-4357)
- Tabassome Simon (ORCID: https://orcid.org/0000-0002-4550-0450)
- Xavier de Lamballerie
- Odile Launay
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Aix-Marseille Université (FR)
- Sanofi (France) (FR)
- Sorbonne Université (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Sanofi (United States) (US)
- Institut de Recherche pour le Développement (FR)
- French Clinical Research Infrastructure Network (FR)
- Centre d'Investigation Clinique de Vaccinologie Cochin-Pasteur (FR)
Publication Details
- Journal
- Vaccines
- Published
- 2024-09-21
- DOI
- https://doi.org/10.3390/vaccines12091079
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi